Researchers identified three microRNAs whose levels were associated with mental performance in cells, mice and humans.
List view / Grid view
Boosting dendritic cells prevented immunotherapy resistance in mouse models, suggesting a new approach to colorectal cancer therapies.
Scientists have identified the OAS1 gene as a risk factor for both Alzheimer's disease and COVID-19, suggesting potential drug targets.
Scientists have identified a subpopulation of mesenchymal stem cells with enhanced bone fracture healing and differentiation abilities.
RGX-202 was found to foil a key pathway that cancer cells rely on for energy in mice, presenting a possible new colorectal cancer therapy.
Researchers have created the first “living medicine” to treat antibiotic-resistant bacteria growing on the surfaces of medical implants.
A protein-based vaccine has proven a promising option to prevent rheumatoid arthritis, improving bone quality in animal models.
Psilera will participate in two studies with the National Institute on Drug Abuse to combat addiction using a novel DMT formulation.
David Julius and Ardem Patapoutian have won the 2021 Nobel Prize for Physiology or Medicine, with their work being used to develop treatments for conditions such as chronic pain.
Scientists have revealed a way to use gene therapy to turn glial brain cells into neurons, restoring vision and potentially restoring motor function.
New evidence suggests that aquaporin 5 (Aqp5) induction promotes corneal epithelial regeneration, which could lead to possible therapies.
Lipophosphonoxins may represent the next generation of antibiotics and can be delivered using a new type of dressing for skin wounds.
Organ-on-a-chip models can provide an alternative to cell cultures, animal models and traditional assays. In this article, Dr Désirée Goubert, Thomas Olivier, Luuk de Haan and Dr Lenie van den Broek explore the advantages of organ-on-a-chip technologies and how they can enable the in vitro study of three-dimensional (3D) cell migration in…
Sinopia has been awarded a $3.3 million Fast-Track SBIR grant to fund the study for its small molecule candidate for Parkinson’s disease.
Limiting neuroinflammation was shown to be a promising approach to treat neurological diseases such as stroke and spinal cord injury in mice.